Full Report

Know the Business

Yatsen is a sub-scale Chinese DTC beauty group whose flagship Perfect Diary made it the poster child of "data-driven" mass color cosmetics in 2020, and whose subsequent five years are a case study in what happens when a paid-traffic engine outruns brand equity. The business has just clawed back to non-GAAP breakeven (FY2025) by leaning on acquired skincare brands — Galénic, DR.WU and Eve Lom — and the bull case now hinges on whether premium skincare can pull the company off the Douyin treadmill before the cash buffer runs out.

How This Business Actually Works

Yatsen rents traffic from Tmall, Douyin and Xiaohongshu, converts it into a high-margin sale, and tries to keep the customer through Weixin "private domain" beauty advisors and an offline experience-store network. Manufacturing is outsourced to ODM/OEM partners (Cosmax, Intercos, Kolmar), so the income statement is dominated by two line items: gross margin (driven by mix) and selling & marketing (driven by traffic price).

The waterfall is the whole story: gross profit of ¥78 per ¥100 of revenue is world-class, but ~¥65 of that goes straight back out to digital platforms and KOLs as selling & marketing (S&M was 64.8% of revenue in Q4 2025, up from 60.1% in Q4 2024 because of Double 11 traffic inflation). Fulfillment, G&A and R&D consume the remaining 12-13 points. The unit therefore breaks even, plus or minus a percent, almost entirely as a function of S&M intensity. A single point of S&M leverage is a point of operating margin.

That mechanic is why management keeps repeating two priorities — mix-shift to skincare (which sustains higher LTV and lower discount intensity) and "stricter ROI discipline" on Douyin spend. It is also why the Color Cosmetics business is being managed for cash, not growth: skincare grew 63.5% in FY2025 while color cosmetics inched up 1.9%. The economic engine here is not "sell more lipsticks" — it is "earn enough customer retention on a serum to stop paying KOLs to find the same shopper again."

The Playing Field

Yatsen sits at the worst possible spot of the global beauty peer set: highest gross margin in the group, lowest operating margin, smallest scale. Local rival Proya Cosmetics — not in the table because it lists in Shenzhen — has quietly become China's #1 domestic cosmetics company by doing the opposite of Yatsen: focus on a single skincare-led brand, run lean, and compound profitably. That is the comparison that matters most strategically, even if the public-market peer set is Western.

Peer financials originally reported in USD; converted to CNY at the 2025-12-31 rate of ¥1 = US$0.14284 for comparability. Ratios are unitless.

The chart isolates the diagnostic: every other peer earns a positive operating margin despite lower gross margin, while Yatsen converts the highest gross margin in the room into the worst operating outcome. ELF runs the same DTC playbook with similar gross margin and clears double-digit operating margins — proof the model can work, but only with brand pull strong enough to avoid the worst paid-traffic auctions. Ulta is structurally different (a retailer, with 39% gross margin but 12.5% operating margin and 44% ROE) — included because it is the asset of choice when investors want exposure to U.S. beauty without single-brand risk. Estée Lauder is the cautionary tale of even prestige-brand pricing power being insufficient when China travel retail rolls over.

What "good" looks like in this industry is neither the highest gross margin nor the largest brand portfolio — it is the lowest paid-traffic dependence per yuan of brand sales. ELF, Proya and (historically) Estée Lauder all clear that bar in different ways. Yatsen does not, yet.

Is This Business Cyclical?

Yatsen's cycle is not the macro consumer cycle (the lipstick effect actually held during Chinese lockdowns); it is a platform-mix cycle. The 2020-2025 chart is one violent swing from a Tmall-and-KOL boom to a Douyin-cost shock and back to a tentative skincare-led recovery. Cycles in this business are about which platform is monetising your traffic, not about consumer wallet share.

The 2020-2022 swing is the entire risk model in microcosm. Yatsen IPO'd at the top of a once-in-a-decade c-beauty bubble — Perfect Diary's Tmall-plus-KOL formula was effectively a regulatory arbitrage on Alibaba's traffic prices — and discovered in 2022 that the same formula on Douyin costs roughly twice as much per acquired customer. Revenue fell 35% in a single year, but more revealing is what fell with it: gross margin actually went up (from 64% in 2020 to 78% in 2025) because management raised price and shut down the loss-making mass-market arm. The cycle hits selling & marketing intensity, not pricing power.

The recovery is real but unfinished. China beauty retail grew 5.1% in FY2025 (8.2% in Q4) per the National Bureau of Statistics; Yatsen's 26.7% top-line growth was largely skincare share-gain on top of that tide. The unanswered question — and the next downturn risk — is what happens when Douyin's CPC environment tightens again, as it did in late 2025 around Double 11 (S&M jumped to 64.8% of revenue). The cycle has one more turn left in it before the model is proven.

The Metrics That Actually Matter

Forget P/E (negative), forget P/B (book value is mostly goodwill already impaired, and accumulated deficit is ¥8.1B). The five numbers that determine whether the equity is a zero or a multi-bagger are below.

Why these five and not the usual ratios:

Skincare share of revenue. Color cosmetics in China is a paid-traffic commodity (no brand pricing power, KOL-driven, Gen-Z fashion cycles); skincare is a habit category with repeat purchase and clinical defensibility. The 33.5% → 53% migration is the single most important value-creation lever, far more than any margin line.

Gross margin. A direct readout of mix shift and discount discipline. A break above 80% would signal the premium-skincare thesis is winning the basket; any fall below 75% means promotion is back.

S&M as % of revenue. The only metric that actually moves the needle on operating margin. Watch it quarter-by-quarter, not annually — the Q4 2025 spike to 64.8% is the warning signal of the moment.

Non-GAAP operating margin. GAAP is dominated by goodwill impairments and SBC; non-GAAP captures whether the underlying engine makes money. FY2025's −2.0% is within striking distance of zero for the first time since 2019.

Cash + short-term investments. With no debt, this is the runway clock. ¥1.05B at end-2025 against ¥94.7M of FY2025 operating cash burn is roughly 11 years of runway at the current rate — but the March 2026 announcement of a US$120M convertible from Trustar Capital (and CEO Huang co-investing personally) suggests management wants firepower for M&A and overseas expansion, not just survival cash.

What I'd Tell a Young Analyst

This is not a beauty company; it is a Douyin-and-Xiaohongshu media-arbitrage business with a cosmetics inventory hedge attached. Underwrite that — not the brand portfolio.

The bull thesis hinges on one specific testable claim: that skincare repeat-purchase and brand pull will let S&M / revenue drift down through the 50s while gross margin holds above 75%. If that happens, operating margin compounds quickly because there is almost no other cost line to fix. If S&M stays stuck above 60%, this is a permanent breakeven asset trading at 0.06x sales because that is what permanent breakeven assets are worth.

Three things to watch over the next four quarters: (1) Skincare share — does it cross 60% in FY2026 as DR.WU and Galénic continue compounding, (2) Q1-Q3 S&M intensity — does Q4 prove to be Double-11-festive noise or the new run-rate, and (3) what management does with the US$120M Trustar money — accretive skincare M&A would extend the thesis; another vanity premium-brand acquisition like Eve Lom (¥403M of impairment in 2024) would tell you the lessons of 2021 were not learned.

Two things the market is probably wrong about. It treats this as a dying mass color-cosmetics brand (it isn't anymore — color is now a managed-decline cash unit and skincare is over half the revenue), and it ignores the option value of a founder-led, debt-free, ¥1B-cash-rich balance sheet at a US$268M market cap when a Chinese skincare consolidation cycle appears to be starting. The bear thesis — that beauty in China is a winner-take-all platform game and Proya already won — is also defensible. Pick a side based on the next two prints, not on the brand story.

The Numbers

Yatsen reports a 78% gross-margin business that has not yet earned an operating yuan in eight years and trades at 0.06x sales because the market has stopped believing the bridge from gross profit to net profit will ever be built. The whole investment case lives in two numbers — selling & marketing as a percent of revenue, and the cash buffer measured in years. Everything else is a derivative of those two. FY2025 was the first year both moved in the right direction at the same time, and the stock is priced as if that will not continue.

Quality Scorecard — Is This Business Built to Last?

External quality scores are unavailable for this ADR; the table below substitutes computed indicators from the eight-year filings. The verdict is unusual: the asset side of the balance sheet is healthier than almost any peer (zero financial debt, ¥1.05B of cash and short-term investments, current ratio of 3.6x), but the income statement still has not converted that fortress into profits.

The scorecard sums to a fortress balance sheet wrapped around a leaky income statement. Predictability is the single weakest line — three platform-mix shocks in five years means historical earnings are a poor estimate of future earnings either way.

Revenue & Earnings Power — Eight Years In One Chart

Two things you cannot un-see: revenue collapsed 35% in a single year (FY2021 to FY2022) and has clawed back only halfway, and the FY2020 net loss of ¥2.5B is roughly half the entire current market cap measured in CNY. The FY2025 net loss of ¥79M is the smallest since 2019 — within striking distance of the breakeven the company has not crossed since the IPO year.

Margin Architecture — The Mix Shift Showing Up In Real Time

Gross margin has expanded 1,560 basis points in seven years — entirely from mix shift toward premium skincare and discount discipline. Operating margin closed a 47-point gap with gross margin in the same window, the bottleneck being selling & marketing intensity (the gap between the green and amber lines). The thesis stands or falls on whether the amber line keeps converging on zero.

The Quarterly Trajectory — Recent Direction Matters Most

Q4 2025 (¥1.36B revenue, −0.9% operating margin) is the strongest single-quarter print since the platform-mix break. The slope of the right-hand chart matters more than any individual point: four straight quarters of compressing operating losses, while revenue re-accelerated to +18% YoY in Q4. This is the "is the corner real?" chart.

Cash Generation — Are The Earnings Real?

Operating cash flow has consistently been less negative than net income — D&A and stock-based compensation absorb a large chunk of the GAAP loss. FY2025 estimated operating cash burn of roughly ¥95M against a ¥79M net loss is a roughly 1.2x ratio — the first year cash burn approached the size of accounting loss in a healthy way. Capex is asset-light at ¥40-60M annually (under 1.5% of revenue), so FCF and CFO march in lockstep. The honest framing: this is no longer a cash-incinerating business; it is a slow-bleed business.

Capital Allocation — Where The IPO Money Went

Yatsen has never paid a dividend and has no debt to service, so capital allocation is binary: cash either sits, gets returned via buybacks, or funds M&A. Of the ¥6.68B raised at the 2020 IPO, roughly ¥4.6B has been consumed by operating losses and acquisition writedowns (Galénic, DR.WU, Eve Lom), and another ¥1.5B has gone out via buybacks and ADS programs. The March 2026 announcement of a US$120M convertible from Trustar Capital signals management wants firepower again — the question is whether the next dollar gets allocated more disciplined than the last one.

Balance Sheet Health — The Reason This Stock Can Survive Anything

Goodwill has been written down from ¥869M (FY2021 peak) to ¥155M — the worst of the M&A-spree damage is already behind in the P&L but still sits in the equity base via the ¥8.1B accumulated deficit. With zero financial debt and ¥1.05B of immediate liquidity against a roughly ¥95M annual operating cash burn, the math says the company has 11 years before the buffer is exhausted at current run-rate. That number could easily double if FY2025's compressing-burn trajectory continues.

Valuation — At The Bottom Of Its Own Range

P/S has spent five quarters compressed in the 0.27–0.30x band — a multiple normally reserved for melting-ice-cube assets. But the financial profile underneath is improving during that compression, not deteriorating: gross margin expanded 200 bps, skincare share crossed half, and operating loss narrowed to under 5% of sales. Either the market is correct that this is a structurally low-quality asset and the multiple is permanent, or the multiple is a 60-70% discount to fair value of a sub-scale brand-house with a fortress balance sheet. EV/Revenue of 0.06x — net of cash, the operating business is being priced near zero — captures how much capitulation is in the quote.

Peer Comparison — Same Industry, Five Different Realities

YSG carries the highest gross margin in the room and the lowest valuation — by an order of magnitude on P/S. The closest economic comparable is COTY (also at trough P/S, also working through brand-portfolio drag), trading at 0.37x sales versus YSG's 0.06x. Pricing YSG at COTY's multiple alone would imply a 6x rerating; that does not happen because the market doubts the demand durability, not the asset quality.

Yatsen is the only dot below the x-axis. Crossing it — even into low single-digit positive operating margin — would relocate this name into the "small-cap c-beauty turnaround" cohort the market currently does not assign to the equity. The chart is the entire investment proposition in one image.

Fair Value & Scenarios

The book-value defense (¥3.0B equity, of which ¥1.05B is cash) sets a hard floor: net cash alone is roughly US$148M against a US$182M market cap, leaving the operating brand portfolio priced at US$34M — for a business that did US$597M in revenue at 78% gross margin. From here, three reasonable scenarios on a 12-month horizon:

The fair-value range is exceptionally wide — that is what trough valuations look like in turnarounds. The asymmetry sits with the Bull case only if the next four prints continue the FY2025 margin trajectory. If they do not, the Bear case is not catastrophic (cash floor protects the equity) but the time-horizon for resolution lengthens past where most active funds will hold the position.

What The Numbers Say

The eight-year ledger confirms that Yatsen's gross margin is durable, rising, and now best-in-peer-group; that the balance sheet is fortress-grade with zero debt and 11+ years of runway; and that FY2025 is the first year all three of revenue growth, margin expansion and cash burn moved in the right direction simultaneously. They contradict the residual market narrative that this is a melting Perfect Diary stub — color cosmetics is now a managed-decline cash unit and the company is materially a skincare house. What to watch in the next four quarters: whether Q1 2026 prints inside the 15-30% revenue-growth guidance, whether selling & marketing as a percent of revenue stays below 60% outside Double-11 quarters, and what the US$120M Trustar convertible buys — accretive skincare brands or another Eve-Lom-style writedown waiting to happen. The numbers say this is a four-quarter binary; the price says it is already over.

Figures converted from CNY at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged. Note that the YSG ADR trades on NYSE in US dollars; CNY values shown are synthetic conversions for cross-comparison with the company's CNY-reporting financials.

Liquidity & Price Picture

YSG is an NYSE-listed ADR (the trading vehicle is in US dollars; this page presents the equivalents in CNY). The stock sits at ¥19.81 — within 4 percent of its 52-week low and 89 percent below its all-time high — having round-tripped a roughly 22-fold rally that ran from March 2024 to June 2025. The longer-term setup is decisively broken; the more important problem for any institutional reader is that even at full market exposure the name barely trades.

1. Where the stock is

The 52-week position percentile sits in the bottom 1 percent of the trailing year, and the negative beta (-1.77) reflects that YSG's largest moves over the trailing year have run counter to the broad US market — a function of stock-specific Chinese consumer-discretionary flows rather than meaningful market hedging.

2. The trend chart — full history with 50/200-day SMAs

Price is decisively below the 200-day — currently ¥43.62, with spot at ¥19.81 (a 55 percent gap). The full lifetime of the ADR has been a downtrend interrupted by two violent counter-rallies (mid-2022 and the March-2024-to-June-2025 squeeze). Both rallies failed to make new lifetime highs; the structure is a sequence of lower highs that has held for five and a half years.

3. Relative strength

The company line — rebased to 100 at April 2023 — captures the entire ¥3.41-to-¥75.95 round trip and is informative on its own: a ~4x move and full give-back in 24 months is a hallmark of speculative, low-float trading rather than a fundamentally driven re-rating. Whether SPY or XLY did anything similar over the same window is the shape of the missing comparison.

4. Momentum — RSI and MACD

RSI sits at 33 — at the 30 oversold line on intraday but not closing oversold. The MACD histogram has just flipped from a deep negative trough back to slightly positive, and the MACD line is converging toward zero from below. The honest reading: a fragile, very early short-term bounce inside a clearly bearish longer-term setup. None of the four counter-rallies on the chart since November 2024 (each marked by a histogram run-up followed by a sharp negative cross) has lasted more than two months — the base rate for these bounces in this name is short and unrewarding.

5. Volume and conviction

The pattern is asymmetric: the two largest volume spikes by share count (November 2023 and March 2024) coincided with sharp price-down days at sub-¥10 levels — capitulation, not accumulation. The June 2025 cluster (covered in the unusual-volume file across 2025-06-09 through 2025-06-25) marked the violent late-stage of the squeeze that took the stock from ¥36 to ¥78 in three weeks; that volume has since reverted to baseline and the price has unwound. The current downtrend is being confirmed by ordinary, sub-50-day-average volume — sellers have stopped pressing, but buyers haven't shown up.

6. Volatility regime

Realized volatility at 67 percent annualised is in the calm-to-normal band — surprisingly low for a stock that had a multi-fold move in the past 18 months. The market is not pricing acute stress here; it is pricing a name that has finished moving violently and has settled into a slow downward grind. That is the most worrying setup for a holder: not a panic to fade, but a quiet bleed.

7. Institutional liquidity panel

This is where the page lands. The fundamentals can be brilliant or terrible — the question for any fund reading this is whether YSG can absorb meaningful capital.

Average daily dollar-equivalent volume of about ¥2.5M is the dominant fact about this stock. A roughly ¥1.86B market-cap ADR turning ¥2.5M of value per day means the entire float would notionally take roughly 200 trading days to change hands at recent rates — and most of that turnover is concentrated in the 2024-2025 squeeze. The annual-turnover figure of 122 percent flatters the picture; it is back-loaded into a six-week window around June 2025.

The median 60-day daily range (high minus low, divided by close) is 5.5 percent — meaningfully above the 2-percent threshold that flags elevated impact cost for large orders. Day-to-day price discovery in YSG happens on tiny size; placing an institutional order would itself move the print.

8. Technical scorecard and stance

Stance: bearish on a 3-to-6 month horizon. Five of six dimensions print neutral or negative; the only thing keeping momentum from a -1 is the very recent MACD histogram flip, and the base rate of bounces in this name is short and unrewarding. The longer-term setup — price 55 percent below the 200-day, third death cross in three years, sitting on the 52-week low — describes a stock that has not yet given the market a reason to want it back. Compounding the picture, the institutional liquidity panel says no real fund can take meaningful exposure here even if the technicals turned: this is a tape for retail flow and small-volume holders.

The two levels that change the view: a weekly close back above ¥27.80 (≈ $4.00) would reclaim the 100-day SMA and break the sequence of lower highs that has defined the post-squeeze unwind — that is the level above which a constructive re-look is warranted. A close below ¥19.11 (≈ $2.75) breaks the 52-week low and opens up a re-test of the 2024 sub-¥10 zone — that is the level below which the bearish thesis converts from drift-lower to structural breakdown.

The People

Governance grade: C+. Yatsen is a founder-controlled Chinese ADR with a 91% voting lock held by one man, growing related-party purchases, and an active securities class action — but it is also genuinely shareholder-active, with a completed ¥1.46B share buyback program, a credible ex-JD/Sina/Goldman independent board, and a CEO who is putting roughly ¥834M of fresh personal capital into the business via a March 2026 convertible.

The People Running This Company

Six names matter. The first three run the company; the second three are the board's check on them.

What They Get Paid

Cash compensation is small, both in absolute terms and against revenue. Equity is where the alignment — and the dilution — actually lives.

The total options outstanding to directors and executives sum to 16.78M Class A shares — economically immaterial to the float, but the strike price tells the story. At US$0.025 per Class A share (US$0.50 per ADS), every grant is deeply in the money against the recent ~US$4 ADS price. These are not pay-for-performance options; they are restricted-stock-equivalent grants disguised as options for tax/structure reasons. That is fine — but it means independent directors are being paid in something that vests regardless of share-price performance.

The aggregate scale of the equity program is the more important number. Of the 249.2M shares authorized under the 2018 Share Option Plan, 219.3M (88%) had already been granted by the end of FY2024. The 2022 Share Incentive Plan layered on an evergreen mechanism: 1.5% of fully-diluted shares plus 1.5% annual top-up for the first two years and 1.0% per year thereafter. That is structural dilution every year for a decade.

Are They Aligned?

This is the case. Yatsen's founder owns 35% of the economics and 91% of the votes. That is alignment of interest and concentration of power, sometimes simultaneously.

Ownership versus voting power

The chart is the story. Class B shares carry 20 votes each and only the founder holds them (600.6M Class B held through Slumdunk Holding, BVI). His 644M total ordinary shares — most of them Class B — give him a 91% lock. Hillhouse, ZhenFund and Banyan together own 33% of the equity but control just 4.7% of the vote. Minority holders cannot win a contested resolution.

Capital allocation behaviour

ADS count has fallen 31% since FY2018 (from 134.9M to 93.1M), driven by a multi-year ¥1.46B (~US$200M) repurchase program now described by management as completed. For a company with negative operating cash flow in 5 of the last 8 years, that is a meaningful capital-allocation choice — it traded balance-sheet flexibility for share-count compression. The ¥1.05B remaining cash and short-term investments at YE2025 (down from ¥5.7B at YE2020) is the receipt for that decision.

Insider activity

There is no Section 16 paper trail (Yatsen is a Foreign Private Issuer — exempt from Form 4 filings), so the standard U.S. insider-trading database is empty. The only individual-level insider transaction in the record is a routine Form 144 in June 2025: an unnamed insider sold 100,000 ADS (≈US$966K, ≈¥6.9M) acquired through the incentive plan in February 2024. That is a vesting-related liquidity sale, not a directional signal.

Related-party transactions — watch this

Purchases of inventory and services from companies under Yatsen's "significant control" have doubled in two years — ¥137.5M → ¥285.5M — and now equal 8.3% of FY2024 revenue. The 20-F discloses these are reviewed by the audit committee and are interest-free, but provides no breakdown by counterparty, no pricing methodology disclosure, and no commentary on why the volume is rising while overall revenue is flat. Separately, Yatsen sells inventory to "a company controlled by our chief executive officer," with the receivable balance from that entity sitting at ¥5.1M at YE2024. None of these numbers are individually large; the trend is what merits attention.

Skin-in-the-game score

A 6, not an 8. The founder's 35% economic stake and his March 2026 convertible cheque are unambiguously aligning. Working against that score: the 20-vote Class B share class neutralises shareholder dissent, the 2022 evergreen plan dilutes minority holders by 1.0–1.5% per year for a decade, related-party purchases are growing, and an unresolved IPO-era class action (see Board Quality below) hangs over the record.

Board Quality

Five directors. Two insiders (Huang, Yang). Three independent. Each independent director chairs one committee, and each is — individually — a credible appointment.

The independent slate is unusually strong for a company at this market-cap (US$268M / ¥1.95B). Sidney Xuande Huang ran finance at JD.com through its full scaling and US listing era; Bonnie Zhang is an active sitting CFO (Sina) and audit-partner alumna; Dr. Jiming Ha brought 13 years of IMF and Goldman Sachs Asia investment-banking judgment. Two of the three are designated audit-committee financial experts, which is one more than the NYSE minimum.

The Verdict

The single fact that would most change this grade is the outcome of the related-party trend. If FY2025 RPT purchases stabilise or shrink and the audit committee discloses a pricing-methodology framework, Yatsen migrates to a B / B+. If the FY2025 20-F shows another 30%+ jump in related-party volume — or any revelation that the convertible warrants meaningfully widen the founder's already-locked voting position — the grade falls to a C / C-.

The Full Story

From a 2020 IPO sold as a "digitally-native, KOL-powered, Perfect Diary masstige" platform to a 2025 pitch built around skincare, R&D, and "science-backed" premium portfolios, Yatsen has changed almost every load-bearing element of its narrative without ever calling it a failure. The skincare pivot management announced at the start of 2022 has, on the second derivative, worked: gross margin moved from 64% to 78%, skincare reached 53% of mix, and FY2025 closed with non-GAAP profitability. But the story arrived three years late, two Eve Lom goodwill writedowns short, and only after every Gen-Z digital-native KPI from the IPO deck was quietly retired. Near-term revenue guidance has been credible (9 of 10 quarters met or beat); long-dated promises have been only partially honored.

1. The Narrative Arc

Six distinct chapters. Color = where management's emphasis sat each year.

The shape of the arc matters more than any single quarter. Revenue peaked in 2021, collapsed 36% in 2022, then ground sideways for two years before reaccelerating in 2025 — a five-year U with a steady, structural margin expansion underneath. Management's tone moved with revenue; the underlying story moved on its own track from "digital DTC" to "premium science."

2. What Management Emphasized — and Then Stopped Emphasizing

Topic-frequency across transcripts and 20-Fs (0 = not mentioned, 3 = heavy emphasis). Read top to bottom: themes that faded sit on top; themes that emerged sit on the bottom.

The chart reads as a single sentence: everything that justified the IPO valuation has been quietly removed from the pitch, and a new set of premium-skincare/R&D talking points has been bolted in. Two reframings stand out:

1. The "32 million DTC customers" metric vanished after FY2021. Management invoked the Personal Information Protection Law as the reason it could no longer disclose the figure — a regulatory excuse that conveniently arrived as the customer base was no longer compounding. It has not returned in any form (DAU, MAU, repurchase rate, cohort retention) in five years.
2. "Direct-to-KOL" / proprietary MCN, the entire IPO competitive moat, is no longer described as a moat. It is mentioned operationally (a livestream here, a partnership there) but never as the structural advantage that originally justified Yatsen's premium-to-peers multiple. The science-backed/patent narrative has fully replaced it.

3. Risk Evolution

Risk-factor emphasis across the five 20-Fs (FY2020–FY2024). 0 = absent, 3 = explicitly elevated.

Three patterns from the risk language are worth flagging.

The IPO-stage risks (KOL dependence, COVID, ICFR material weakness, HFCAA) all faded — some because the underlying problem genuinely receded (HFCAA after PCAOB inspection, ICFR after remediation), some because management stopped narrating them as central. KOL dependence in particular went from a top-three risk in 2020-21 to a perfunctory mention by 2024.

The acquisition-era risks (goodwill impairment, integration, color cosmetics weakness) showed up exactly when they should have. Goodwill-impairment language strengthened in FY2022 and FY2023 — and in both cases the impairment then materialized (¥354M in 2023, ¥403M in 2024 against Eve Lom). The risk factor was honest; the conference-call narrative around Eve Lom was not (see Section 4).

Going-concern language has never appeared. Across five 20-Fs, despite cumulative net losses near ¥7.5B since IPO, no auditor or filing has flagged substantial doubt. This is consistent with the balance sheet, which retained material net cash through the entire crisis.

4. How They Handled Bad News

Three episodes show the pattern: external blame first, financial detail second, narrative continuity third.

FY2022 revenue collapse (-36.5%). The official explanation in the FY2022 20-F: "recurrent COVID-19 outbreaks and related lockdowns," intensifying competition, weak consumer sentiment, and "color cosmetics market faced prolonged headwinds." Notably absent: any discussion that the 32M-DTC-customer cohort was no longer compounding, that Perfect Diary had crossed a brand-fatigue inflection, or that the masstige positioning had been competed away by Douyin-native challengers. The five-year transformation plan — announced in early 2022, before the worst of the collapse — was repeatedly invoked to argue that the strategy was already in motion, recasting a forced retreat as a planned pivot.

Eve Lom goodwill impairments (¥354M FY2023, ¥403M FY2024 — cumulative ¥757M / ~$105M against the 2021 acquisition price). Both writedowns were disclosed with the same boilerplate language and immediately followed by a brand re-affirmation:

"The carrying value of the Eve Lom reporting unit exceeded its fair value… due to weaker operating results than expected at the time of acquisition. Despite challenges in the market environment and ongoing competition, we still see potential in the brand." — Q4 2023 release

What makes the language revealing is the context. In Q3 2022 management had specifically called out Eve Lom's "robust growth despite the challenging industry environments," and in Q4 2022 cited 99.3% combined revenue growth across Galénic / DR.WU / Eve Lom. The brand was being celebrated on the call while it was simultaneously being impaired on the balance sheet. The second impairment a year later was barely discussed beyond the financial walk-through.

Skincare disappointments in 2023-2024. When skincare itself stuttered — Q3 2023 declined 4.1% YoY, Q1 2024 was flat, Q2 2024 forced a mid-year guidance cut — the explanations again externalized: Abby's Choice phase-out (Q3 2023), seasonal low (Q1 2024), "softer performance of China's beauty market" (Q2 2024). The skincare-led recovery thesis was never re-litigated; the next quarter's results were always framed as the resumption of the original plan.

5. Guidance Track Record

Yatsen guides one quarter forward in revenue (a YoY % range). Eleven guides issued; ten now have outcomes.

Near-term revenue guidance has been credible. The single clean miss (Q2 2024) was acknowledged in real time with a mid-year revision. Beats clustered through the post-collapse recovery (Q1–Q4 2023), exactly when management most needed the credibility — easier to read as conservative guides during a base-low recovery than as systematic outperformance.

The bigger promises track less cleanly:

Credibility: 6/10. Near-term revenue guidance is reliably hit, often by setting a conservative range. The skincare-led pivot has, on the second derivative, delivered: gross margin from 64% to 78%, skincare from 4% of mix to 53%, non-GAAP profitability achieved. But the guidance track record on multi-year promises is mixed — "near to mid-term" profitability took three years, "the decline has bottomed out" was premature by a year, and two Eve Lom goodwill writedowns followed quarters in which management was actively celebrating the brand. There has not been a single earnings call in which an earlier strategic claim was explicitly retracted; setbacks are absorbed into a smooth narrative arc. The pivot worked; the messaging around it has not been audited.

6. What the Story Is Now

The pitch as of Q4 2025: a multi-brand, premium-skincare-led, R&D-driven beauty platform with proprietary patent IP, AI-assisted molecular research, and a global footprint anchored in France (Galénic), Britain (Eve Lom), and Taiwan (DR.WU). Skincare is 61% of Q4 revenue and growing materially faster than color cosmetics. Gross margin sits at 78%. Non-GAAP profitability has been delivered for the full year. A $200M buyback is complete; a $120M convertible private placement (Trustar plus founder Jinfeng Huang) signals internal confidence and provides capital for "research, logistics, international expansion, and acquisition."

"From trend-driven to science-backed, we now offer products across all major segments." — CEO David Huang, Q4 2025

The line is the entire repositioning in one sentence. It is also the line that the rest of this tab should make a reader careful about.

What has been de-risked.

• The skincare-share question. Skincare actually hit and exceeded the 50% threshold management invoked in Q4 2022.
• The gross-margin question. The mix shift to clinical and premium brands has compounded into structurally higher GM (64% → 78%).
• The going-concern question. Despite five years of losses and two material impairments, the balance sheet has held; no auditor language to date.
• The HFCAA / ICFR / China-listing tail risks that dominated the 2021-22 risk factors have largely receded.

What still looks stretched.

• The Eve Lom thesis. ¥757M of cumulative goodwill impaired against the original 2021 purchase price. The brand is still being repositioned ("emotional skincare," Oxford summit, dermatology congresses) — the investor pitch outpaces the financial recovery.
• The "AI / cellular / patents" frame is new. It appeared in Q4 2025 transcripts after being silent for three years. Investors should treat it as a freshly added narrative and look for it to be quantified (specific patent revenue, specific AI-discovered molecules in market) before crediting it.
• Color cosmetics has been deemphasized but is still ~40% of revenue. The structural decline of that segment is being managed, not solved — Perfect Diary's repositioning is a Biolip-driven niche play, not a return to mass relevance.
• The capital architecture. A $120M convertible private placement to the founder and a controlling-shareholder vehicle (Trustar) is unusual and dilutive; it is being framed as a vote of confidence but it is also a discounted insider transaction that bypassed the public market.

What the reader should believe vs discount.

Believe. The mix shift to skincare. The gross-margin expansion. The cost discipline. The near-term guidance. The fact that management can produce non-GAAP profitability when it chooses to.

Discount. The new "science-backed / AI / cellular" framing — until it appears in segment economics rather than press releases. Any forward statement about Eve Lom specifically. Any claim about international expansion until it shows up as a disclosed revenue line. The implicit suggestion that the 2020 IPO-era story merely "evolved" — most of it was retired, and the current portfolio of acquired premium brands is the second strategy, not a refinement of the first.

The current Yatsen is a real company doing real things, in real margins, with real if modest profitability. It is not the Yatsen that came public in 2020 — and the value of reading these filings back to the beginning is precisely the realization that almost none of the original thesis is still load-bearing.

What's Next

The next 3–6 months are unusually loaded for a name this small. Two prints that arrive before mid-August will settle the central operating question, and the second tranche of the founder-and-Trustar convertible will be deployed into the same window. Today is 2026-04-27.

What the market is watching most closely. Two numbers, in this order: (1) S&M as a percent of revenue in Q1 2026 — the single line item that printed at 64.8% in Q4 2025 and that the entire FY2026 thesis depends on drifting back into the 50s; (2) non-GAAP operating margin holding at or above zero — the four-quarter compression trajectory crossing the breakeven line in print, not in adjustment. The convertible second tranche and any acquisition announcement will be read in the context of those two prints. Management has guided Q1 2026 net revenue to ¥958.6M–¥1.08B (+15% to +30% YoY); the consensus expectation is that the midpoint comes in but the cost line is the real test.

For / Against / My View

The Bull and Bear cases below are drawn directly from bull-claude.md and bear-claude.md — three sharpest points each, evidence intact. The Tensions section identifies where the two essays argue about the same fact and the signal that resolves each.

For

Bull's primary catalyst: Q1 and Q2 2026 prints inside the +15% to +30% revenue guidance with non-GAAP operating margin holding at or above zero — the four-quarter trajectory crossing the breakeven line in print, not in adjustment. Skincare share crossing 60% for FY2026 is the second leg. Bull's disconfirming signal: S&M as a percent of revenue staying above 65% for two consecutive non-Q4 (non-Double-11) quarters, or a third goodwill writedown — either on existing Eve Lom carrying value or on a freshly-deployed Trustar convertible acquisition.

Against

Bear's primary trigger: Q1 2026 print fails to hold S&M below 60%, or management announces a premium-skincare acquisition above ¥500M before two clean operating-positive quarters. Bear's covering signal: Two consecutive quarters of S&M below 58% of revenue and non-GAAP operating margin above zero without a corresponding skincare-share retrenchment.

The Tensions

1. Q4 2025 — vindication or warning?

Bull reads Q4 2025 as the inflection: operating margin compressed from −34% (Q4 2024) all the way to −0.9% on +18% revenue, gross margin 79.2%, the four-quarter chart that the equity is refusing to re-rate. Bear reads the same quarter as the warning: selling & marketing jumped to 64.8% of revenue from 60.1% the prior Q4, and that is the very line item the FY2026 thesis depends on. Both cite the Q4 2025 print. This resolves on the Q1 2026 print, due mid-May 2026 — specifically whether S&M holds below 60% and non-GAAP operating margin sits at or above zero. Both, or the bull case is finished for at least another quarter.

2. The Trustar convertible — alignment or value extraction?

Bull reads CEO Huang personally writing ~¥417M into the convertible at a 89% drawdown as the strongest available "I believe" disclosure — a founder doubling down with personal capital. Bear reads the same deal as a related-party financing where the controlling shareholder gets a 1.5% coupon, a 20% conversion premium, and warrants equal to one-tenth of conversion shares — terms minority holders cannot match — with proceeds explicitly earmarked for the same "premium brand acquisition + international expansion" mandate that produced ¥757M of Eve Lom impairments. Both cite the March 2026 ¥834M Trustar convertible. This resolves on how the proceeds are deployed by Q3 2026 — a sub-¥500M bolt-on or a buyback signals discipline; another ¥500M-plus premium-brand acquisition before two clean operating-positive quarters confirms the bear's "lessons-of-2021-not-learned" framing.

3. The ¥1.05B net cash position — downside floor or M&A war chest?

Bull reads ¥1.05B of cash and short-term investments inside a ¥1.87B market cap as the downside floor — the operating business is being priced near zero against a balance sheet with zero financial debt. Bear reads the same ¥1.05B as not a floor for minority holders because the cash is earmarked for acquisitions and overseas expansion, not buybacks, and the eight-year track record is ¥4.6B of IPO money consumed by operating losses and writedowns. Both cite the FY2025 year-end cash position. This resolves on the next capital-allocation decision — a buyback authorisation or a sub-¥200M tuck-in proves the floor is real; a ¥500M-plus premium-brand acquisition proves the cash is dry powder for the same playbook.

My View

Close call but the slight edge sits with the bear. The single sharpest datum on the page is that S&M ratio printing 64.8% in the very quarter the bull case rests on — management's primary operating lever moved against the thesis on the most recent print, in the most important quarter of the year, and that's not noise. The Trustar convertible compounds the worry rather than resolving it: when a 91%-voting founder takes related-party paper in his own company at the bottom on cheap terms, it can be alignment, but it can also be the only-buyer signal, and the earmark — premium-brand M&A and overseas expansion — points back at the exact playbook that produced ¥757M of Eve Lom impairments. I'd wait for the Q1 2026 print due mid-May. The condition that would flip me toward the bull side: Q1 2026 prints S&M below 60% AND non-GAAP operating margin at or above zero, with skincare share holding above 60%. That is the same data point the bear used to dismiss the inflection — if it travels into a non-Double-11 quarter, the trough multiple becomes interesting in a way it isn't today.

What the Internet Reveals

The Bottom Line from the Web

Two events in the last 90 days reframe the Yatsen story: a ¥860M (US$120M) related-party convertible note placement announced March 11, 2026 — funded by founder/CEO Jinfeng Huang and Trustar Capital at a $4.63 conversion price — and a first-ever full-year non-GAAP profit (¥8.4M) for FY2025 disclosed March 2, 2026 alongside +26.7% revenue growth. The market read the combination as bearish on net: shares fell ~9% on the earnings print and another ~10% on the convertible deal, and YSG is now down 97% since its 2020 IPO, trading near the bottom of its 52-week range despite analyst median targets at $5.80 (implied +76%).

What Matters Most

1. Founder + Trustar fund a ¥860M convertible — bullish signal or shareholder dilution?

The deal is dual-edged. Bullish read: the founder is putting fresh capital in personally — proceeds fund R&D, supply-chain integration, overseas expansion and M&A. Bearish read: this is a related-party financing where the controlling shareholder (Huang already owns ~35%) gets cheap convertible terms (1.5% coupon, modest 20% conversion premium) that minority shareholders cannot match, and the warrant kicker compounds dilution. With ¥1.05B cash on the balance sheet at year-end, the strategic necessity of the raise is also questionable.

2. FY2025: first non-GAAP profit since IPO, but Q4 quality deteriorated

The FY headline is genuinely a turnaround — but Q4 alone shows cracks. Q4 net revenue rose 20.1% to ¥1.38B, yet Q4 non-GAAP net income fell to ¥41.2M from ¥107M the prior year, selling & marketing rose to 64.8% of revenue on higher traffic acquisition costs during shopping festivals, and operating cash flow used ¥69.4M in Q4 (¥94.7M used for FY). Color cosmetics revenue declined 9.1% YoY in Q4, validating the bearish thesis that the legacy Perfect Diary engine is still shrinking. Stock fell 8.99% on the print.

3. Stock down 97% since IPO — and 33% in the last year

4. Securities class action lawsuit alleges IPO-era misrepresentations

The litigation centers on the IPO disclosures. No public update in the last 90 days, but the class action remains an unresolved overhang.

5. Insider Form 144 sale by company executive (June 2025)

The Form 144 doesn't name the filer publicly but signals an executive monetizing equity comp at a depressed price. Note that the insider transaction percent shown on Finviz is 0% — small relative to total shares.

6. Analyst coverage is thin and divided

The dispersion ($2.57 fair value vs $5.80 target) reflects deep uncertainty about whether the skincare pivot is durable.

7. Q1 2026 guidance: +15% to +30% revenue growth

Management guided Q1 2026 net revenues to ¥958.6M–¥1.08B — a 15% to 30% YoY range. The midpoint (~22%) is a deceleration from FY2025's +26.7% but consistent with "growth at scale" framing. Source: stocktitan.net/news/YSG.

8. Skincare is now the majority of revenue — pivot is real

Skincare brands (Galénic, Dr.WU mainland China, Eve Lom, EANTiM) reached 53.0% of FY2025 revenue with +63.5% YoY growth, while Q4 skincare alone was 61.1% of revenue with +51.9% growth. Color cosmetics (Perfect Diary, Little Ondine, Pink Bear) declined 9.1% YoY in Q4. The portfolio mix shift is the central driver of the gross margin lift to 78.2%. Source: yahoo finance Q4 2025, yahoo finance Q2 2025.

9. Cash runway is workable but not abundant

Cash, restricted cash and short-term investments at Dec 31, 2025: ¥1.05B. The convertible adds another ~¥860M (≈¥430M in tranche 1 around March 2026, ¥430M in tranche 2 later in 2026). Against FY2025 operating cash burn of ¥94.7M, the company has multiple years of runway. Total debt remains low (Finviz: Debt/Equity 0.06).

10. China beauty market: large, fragmented, accelerating in skincare

The Chinese beauty market exceeds ¥400B (~US$57B) and remains fragmented — even top players hold only single-digit market share, per CEO Huang's April 2025 Bloomberg China Show interview. Global personal care market expected to reach US$563B in 2026 growing at 5.24% CAGR; Asia-Pacific is the fastest-growing region (+7.49% CAGR through 2031), with skincare leading at 33.4% of category share. Source: mordorintelligence.com personal care report, yahoo finance Huang interview.

Recent News Timeline

What the Specialists Asked

Insider Spotlight

Key patterns:

• Top 3 shareholders own 54% — minority shareholders have limited governance leverage, especially after the March 2026 dilutive structure.
• Founder is doubling down economically via the convertible, but he is also the controlling counterparty — so the signal is muddied.
• No public open-market insider buying captured in the searches; only one insider sale (Form 144, June 2025).

Industry Context

The global personal care market is structurally healthy but China-specific dynamics are mixed:

What this means for Yatsen:

• Tailwind: Asia-Pacific is the largest and fastest-growing region; skincare is the highest-share product category at ~33%; premium products growing ~7%+ CAGR (faster than mass).
• Headwind: China color cosmetics, where Perfect Diary built its franchise, has slowed materially (Yatsen's color cosmetics −9.1% in Q4 2025 vs. industry segment estimates above). Premium skincare is the right pivot, but Yatsen competes head-to-head with L'Oréal, Estée Lauder, Procter & Gamble brands at scale.
• Structural: Even Chinese leaders hold only single-digit share (per CEO Huang) — the market is fragmented enough to support the "agile innovator" thesis, but it also means no incumbent has built a defensible moat through scale alone.